Malignant Lymphoma in a Renal Transplant Recipient Treated With Antithymocyte Globulin

Ao, Kheirbek; Zv, Molnar; Choudhury, AK; Wp, Geis; Jt, Daugirdas; Je, Hano; Ts, Ing

doi:10.1097/00007890-198303000-00014

Cited by 12 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same thing was described long ago after reduction or withdrawal of azathioprine, prednisone, and antilymphocyte globulin 16,17 and documented in detail by Iwatsuki et al 18 and Geis et al 5 Of the 5 patients reported by Geis 5 and Iwatsuki 18 and their associates whose lymphomas regressed, 1 later acquired a different neoplasm and the other 4 remained tumour free. 20 As with kidney and liver recipients, the only survivors among the 5 heart or heart-lung recipients in the present series were 2 who had withdrawal of immunosuppression. In 1 of the other 3, the diagnosis was not made until necropsy.…”

Section: Discussionmentioning

confidence: 63%

Reversibility of Lymphomas and Lymphoproliferative Lesions Developing Under Cyclosporin-Steroid Therapy

Starzl¹,

Porter²,

Iwatsuki³

et al. 1984

The Lancet

1,133

451

View full text Add to dashboard Cite

SummaryPost-transplant lymphomas or other lymphoproliferative lesions, which were usually associated with Epstein-Barr virus infections, developed in 8, 4, 3, and 2 recipients, respectively, of cadaveric kidney, liver, heart, and heart-lung homografts. Reduction or discontinuance of immunosuppression caused regression of the lesions, often without subsequent rejection of the grafts. Chemotherapy and irradiation were not valuable. The findings may influence policies about treating other kinds of posttransplantation neoplasms.

show abstract

Section: Discussionmentioning

confidence: 63%

Reversibility of Lymphomas and Lymphoproliferative Lesions Developing Under Cyclosporin-Steroid Therapy

Starzl¹,

Porter²,

Iwatsuki³

et al. 1984

The Lancet

1,133

451

View full text Add to dashboard Cite

show abstract

“…Hence, doses of ALG, prednisone, and other cytotoxic agents may be augmented needlessly. Be sides further complicating the immunohematological problem at hand, high doses of antilymphocyte globulin would increase the risk of adverse consequences of immunosup pression, including infection [1,7,11] and possibly neoplasia [10,20], (2) Transfusion in the face of incompatible crossmatches due to MALG antibody alone would appear to be safe, if performed cau tiously. Negative results of screening proce dures for red cell antibodies, performed be fore institution of therapy with MALG, strengthen the validity of this premise in any individual case.…”

Section: Discussionmentioning

confidence: 99%

Passively Acquired Antibody Directed at Human Erythrocytes Seen during Therapy with Minnesota Antilymphohlast Globulin

Wick¹,

DeLong²,

Moore³

1985

Vox Sanguinis

View full text Add to dashboard Cite

6 renal transplant patients, seen at the Mayo Clinic between July 1982 and April 1983, received Minnesota antilymphoblast globulin (MALG) for treatment of allograft rejection and demonstrated warm-acting ‘auto’-antibodies during such therapy. These antibodies represented xenogeneic reactivity in equine MALG, rather than the products of patient-derived immune responses, since they were not detected before or after the period of therapy with this immunosuppressive agent in any of the 6 cases. They interfered with crossmatch procedures for red cell transfusion, and were only variably removed by autoabsorption techniques. Heat treatment of sera containing MALG-related red cell antibodies was ineffective in abrogating their reactivity and also compromised the reactivity of some red cell alloantibodies which were tested as controls. Transfusion of ‘least-incompatible’ red blood cells had no adverse effects in 2 cases where it was necessitated by clinical circumstances, despite an inability to obtain suitable serological samples for crossmatching

show abstract

First report of a B cell lymphoproliferative disorder arising in a patient treated with immune suppressants for severe aplastic anemia

1996

View full text Add to dashboard Cite

Aplastic anemia is a disorder characterized by pancytopenia and bone marrow hypocellularity. There is some evidence that aplastic anemia may be due to suppression of hematopoiesis by activated T-suppressor cells. Thus, immunosuppressive agents have been used as an alternative to bone marrow transplantation for treatment. We report on a unique case of a patient with aplastic anemia who was treated with a course of immunosuppression including cyclosporine (CSA), anti-thymocyte globulin (ATG), and prednisone. Five months after this treatment, the patient developed a B cell lymphoproliferative disorder which was successfully treated with radiation therapy. Prior reports of CSA-associated lymphoproliferative disorders have appeared in the literature as potential side effects of immunosuppression following transplantation. This is the first report of a lymphoproliferative disorder associated with immunosuppressive treatment of aplastic anemia in a nontransplant setting. Thus, when presenting options for treatment of aplastic anemia, lymphoproliferative disorders should be included as a rare complication of immunosuppressive therapy.

show abstract

Malignant Lymphoma in a Renal Transplant Recipient Treated With Antithymocyte Globulin

Cited by 12 publications

References 0 publications

Reversibility of Lymphomas and Lymphoproliferative Lesions Developing Under Cyclosporin-Steroid Therapy

Reversibility of Lymphomas and Lymphoproliferative Lesions Developing Under Cyclosporin-Steroid Therapy

Passively Acquired Antibody Directed at Human Erythrocytes Seen during Therapy with Minnesota Antilymphohlast Globulin

First report of a B cell lymphoproliferative disorder arising in a patient treated with immune suppressants for severe aplastic anemia

Contact Info

Product

Resources

About